Robert W. Baird Issues Pessimistic Forecast for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price decreased by investment analysts at Robert W. Baird from $26.00 to $20.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price objective points to a potential upside of 138.66% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on ENTA. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th. JPMorgan Chase & Co. reduced their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research report on Tuesday, August 6th. JMP Securities reissued a “market outperform” rating and set a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Enanta Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Enanta Pharmaceuticals Stock Down 7.0 %

NASDAQ ENTA traded down $0.63 during trading hours on Tuesday, hitting $8.38. The company had a trading volume of 91,960 shares, compared to its average volume of 199,973. Enanta Pharmaceuticals has a fifty-two week low of $8.31 and a fifty-two week high of $17.80. The firm has a market cap of $177.57 million, a P/E ratio of -1.54 and a beta of 0.56. The business has a fifty day simple moving average of $11.03 and a 200-day simple moving average of $12.36.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Large investors have recently made changes to their positions in the business. Krensavage Asset Management LLC lifted its stake in Enanta Pharmaceuticals by 19.7% during the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after purchasing an additional 246,736 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after buying an additional 134,292 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth $1,243,000. Point72 Asset Management L.P. acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter worth $903,000. Finally, Farallon Capital Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 3.5% during the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after purchasing an additional 70,000 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.